Summary:
In adults with type 2 diabetes participating in the SURPASS-2 phase 3 trial across multiple countries, once-weekly subcutaneous tirzepatide significantly improved markers of β-cell function, insulin sensitivity, and fasting biomarkers compared to weekly semaglutide under similar conditions. Reductions in HbA1c and weight were consistently greater with tirzepatide, regardless of baseline metabolic status.
| PICO | Description |
|---|---|
| Population | A total of 1,879 adult participants with type 2 diabetes who were part of the SURPASS-2 phase 3 trial conducted across 128 sites in 8 countries. |
| Intervention | Once-weekly subcutaneous Tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg for a duration of 40 weeks. |
| Comparison | Semaglutide 1 mg administered weekly as a comparator under similar trial conditions for 40 weeks. |
| Outcome | Tirzepatide demonstrated significantly greater improvements compared to semaglutide in markers of β-cell function (HOMA2-B increase: 96.9-120.4% vs. 84.0%, P < .05), insulin sensitivity (HOMA2-IR reduction: 15.5%-24.0% vs. 5.1%, P < .05), and fasting biomarkers (C-peptide reductions: 5.2%-6.0% vs. an increase of 3.3%, glucagon reduction: 53.0%-55.3% vs. 47.7%, P < .05). Reductions in HbA1c and weight were consistently greater with Tirzepatide regardless of baseline β-cell function and insulin resistance. |
Source: Frias, Juan P., et al. “Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).” J Clin Endocrinol Metab, 2024. Read article here.
